Retatrutide 20mg Research Pen

Retatrutide 20mg (10 x 2mg Research Dose)

Product Overview:

Retatrutide is a cutting-edge synthetic research peptide currently under investigation for its role as a triple agonisttargeting the GLP-1, GIP, and glucagon receptors. This unique mechanism has made Retatrutide a focus of significant scientific attention due to its potential impact on metabolic regulation, glucose control, and energy expenditure.

The Vitalis Retatrutide 20mg format provides 10 x 2mg precisely measured research doses, allowing for controlled and repeatable use within a research setting. Each batch is produced to exacting laboratory standards and verified for purity, stability, and consistency, ensuring researchers have complete confidence in their data.

Key Features:

• Concentration: 20mg total (10 x 2mg research doses)

• Form: Multidose vial for reconstitution

• Purity: ≥ 99% (HPLC tested)

• Manufactured: In controlled laboratory environments to research-grade standards

• Storage: Store in a cool, dry place. Once reconstituted, refrigerate at 2–8°C.

• Purpose: For laboratory and scientific research only

Research Interest Areas:

• Investigated for its potential to enhance glucose metabolism and insulin sensitivity

• Studied for its possible influence on body composition and energy regulation

• Research into multi-receptor peptide activity for advanced metabolic studies

• Potential applications in endocrine and metabolic function modeling

Why Choose Vitalis Peptides:
Vitalis sets the benchmark for quality in the peptide research sector. Every product is formulated for scientific precision and supported by independent third-party laboratory analysis. Researchers can trust in the integrity, reproducibility, and verified purity of each compound—ensuring that every experiment is built on a foundation of reliability and accuracy.

Important Notice:
All Vitalis products are intended strictly for laboratory research use only. They are not for human consumption, and not sold as drugs, food, or supplements.